Postherpetic neuralgia is the burning nerve pain that persists after shingles clears. It is common, it is difficult to treat, and conventional analgesics often fail against it.
Palmitoylethanolamide appears on almost every list of options for it. The honest version of that list is much shorter than it looks.
The entire published evidence base for PEA in this specific condition is one open-label trial in eight patients using a cream, and two case reports. This article is short on claims because the literature is short on studies, and padding it would misrepresent what exists.
Key Takeaways
- In an open-labelled trial, 8 patients with facial postherpetic neuralgia received a cream containing PEA, and 5 of the 8 experienced a mean pain reduction of 87.8% [1].
- That study was topical, open-label, and had no control group [1]. It is the largest study in this indication.
- A case report describes a 67-year-old man with three years of postherpetic neuralgia who reported relief within 48 hours on oral PEA at 900 mg daily [2].
- A case series describes PEA use across neuropathic pain of various causes, including postherpetic neuralgia, in patients poorly responsive to standard therapies [3].
- No randomized controlled trial of PEA in postherpetic neuralgia has been published. Anyone claiming proven efficacy here is describing evidence that does not exist.
Why This Article Is Short
Most pages about supplements for shingles pain are long. They expand a thin evidence base with mechanism, general nerve pain research and lifestyle advice until it reads like a body of knowledge.
The evidence here is three papers. Presenting them accurately takes less space than dressing them up, and a reader deciding whether to spend money on this deserves to know the size of what is behind the recommendation.
The Only Trial: Eight Patients, a Cream
Postherpetic neuralgia is a frequent adverse event in herpes zoster patients and is difficult to treat, with conventional analgesic therapy often failing to reduce the burning pain transmitted by unmyelinated nerve fibres [1]. The authors reasoned that those nerves express cannabinoid receptors involved in pain signalling, which made a topical cannabinoid agonist worth trying for local burning pain[1]. PEA itself does not activate CB1 or CB2 receptors, so that rationale does not describe how PEA works [5][6].
Research note: In an open-label trial of 8 patients with facial postherpetic neuralgia, a topical PEA cream gave an average 87.8% pain reduction in the 5 responders [1].
In an open-labelled trial, 8 patients with facial postherpetic neuralgia received a cream containing N-palmitoylethanolamine (PEA), which the authors described as a cannabinoid receptor agonist [5][6], with symptoms scored on a visual analogue scale [1]. Five of the eight, 62.5%, experienced a mean pain reduction of 87.8% [1]. Therapy was tolerated by all patients, with no unpleasant sensations or adverse events [1]. The authors conclude that topical cannabinoid agonists are an effective and well-tolerated adjuvant therapy option [1].
Four things about that study set the ceiling on what it can support. It had eight patients. It was open-label, so everyone knew what they were getting. There was no control group. And the response rate was five of eight, meaning three people did not respond, which the headline percentage obscures.
The word adjuvant in the title is also load-bearing. This was tested as an addition to existing therapy, not as a replacement for it.
It is also topical. A cream applied to the painful area of the face is not the same intervention as a capsule, and this site covers that oral-versus-topical split in more detail in its article on PEA creams for eczema and itch, where the same pattern appears.
The Case Reports
A case study describes a 67-year-old man with ongoing postherpetic neuralgia over a three-year period following complications from shingles [2]. PEA is reported to have produced effective pain relief within 48 hours at a daily dose of 900 mg, roughly 10 mg per kilogram, and the author suggests PEA may offer a valid nutraceutical option for practitioners [2].
This is the only description of oral PEA specifically in postherpetic neuralgia, and it is a single patient. Relief within 48 hours in a condition that has persisted for three years is striking, and single-patient reports of striking responses are exactly the type of evidence most vulnerable to being unrepresentative. Cases that respond get written up. Cases that do not, generally do not.
A broader case series reports on PEA in neuropathic pain associated with various pathological conditions in patients poorly responsive to standard therapies [3]. The paper lists the conditions where PEA has been studied, including diabetic neuropathy, chemotherapy-induced peripheral neuropathy, carpal tunnel syndrome, sciatic pain, osteoarthritis, low back pain, failed back surgery syndrome, dental pain, neuropathic pain in stroke and multiple sclerosis, chronic pelvic pain, postherpetic neuralgia and vaginal pain [3]. It also notes that because PEA is an endogenous modulator and a component of foods such as eggs and milk, no serious side effects or drug interactions have been reported [3].
That condition list is worth understanding correctly. It describes where the compound has been investigated, not where it has been proven. Several of those indications have randomized trials behind them and this site covers them individually. Postherpetic neuralgia is not one of them.
Why the Gap Exists
It is not obvious why this indication was never properly tested, since the mechanism is at least as plausible here as elsewhere. PEA acts mainly through PPAR-alpha with proposed activity at TRPV1 and GPR55 and has anti-inflammatory and analgesic properties. Trials report few adverse events, mostly mild gastrointestinal upset or dizziness [7][8][9]. Neuropathic pain is where the compound has been studied most.
Part of the answer may be timing. The vaccine has changed the epidemiology, and much of the neuropathic pain research effort went into diabetic neuropathy and chemotherapy-induced neuropathy, where patient numbers for recruitment are larger and more predictable.
Whatever the reason, the practical consequence is the same. Someone with postherpetic neuralgia considering PEA is not choosing between a proven and an unproven option. They are considering an untested one, alongside treatments that do have trial evidence.
What to Do With This
Postherpetic neuralgia has established treatments with real evidence behind them, and they belong in the conversation first. Pain that persists after shingles warrants proper management rather than self-treatment, particularly facial involvement, which can affect the eye.
If PEA is under consideration as an addition, the honest framing is that the evidence in this condition consists of one small open trial of a cream [1] and two case reports [2][3]. The compound’s tolerability is well documented [4], which lowers the risk of trying it, and low risk is not the same as demonstrated benefit.
The stronger PEA evidence in nerve pain sits elsewhere, in diabetic neuropathy, sciatica and chemotherapy-induced peripheral neuropathy, each of which this site covers separately. Reading across from those to shingles pain is an inference, not a finding.
Frequently Asked Questions
Does PEA help postherpetic neuralgia?
The only study is an open-label trial of a PEA cream in 8 patients, where 5 reported a mean pain reduction of 87.8% [1]. No randomized controlled trial exists in this condition.
What oral dose has been reported?
A single case report describes 900 mg daily, about 10 mg per kilogram, with relief reported within 48 hours in one 67-year-old patient [2].
Was the cream or the capsule tested?
The only trial used a topical cream applied to facial postherpetic neuralgia [1]. The oral evidence is one case report [2].
Why is PEA listed for shingles pain everywhere?
Largely because review papers list postherpetic neuralgia among conditions where PEA has been investigated [3]. Being investigated is not the same as being shown to work.
Is it safe to try?
Trials report few adverse events with PEA, mostly mild gastrointestinal upset or dizziness, and none occurred in the topical trial[1][9]. Good tolerability is a reason it is low-risk to discuss with a clinician, not evidence that it works.
References
- Phan NQ, Siepmann D, Gralow I, Ständer S. Adjuvant topical therapy with a cannabinoid receptor agonist in facial postherpetic neuralgia. J Dtsch Dermatol Ges (2010). PMID 19744255
- Kamper D. Palmitoylethanolamide (PEA) in the treatment of neuropathic pain: a case study. Nutr Health (2022). PMID 34289728
- Hesselink JMK, Hekker TAM. Therapeutic utility of palmitoylethanolamide in the treatment of neuropathic pain associated with various pathological conditions: a case series. J Pain Res (2012). PMID 23166447
- Rankin L, Fowler CJ. The Basal Pharmacology of Palmitoylethanolamide. Int J Mol Sci (2020). PMID 33114698
- Vincenzo Di Marzo et al. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochemical Journal (2001). PMID 11485574
- Sugiura T et al. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. The Journal of biological chemistry (2000). PMID 10617657
- Roncati L et al. Micronized / ultramicronized palmitoylethanolamide (PEA) as natural neuroprotector against COVID-19 inflammation. Prostaglandins & other lipid mediators (2021). PMID 33636368
- Im DS GPR119 and GPR55 as Receptors for Fatty Acid Ethanolamides, Oleoylethanolamide and Palmitoylethanolamide. International journal of molecular sciences (2021). PMID 33494185
- Wang Y et al. Palmitoylethanolamide in the Treatment of Pain and Its Clinical Application Prospects. Drug design, development and therapy (2025). PMID 40827226
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.